Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5936
    -0.0013 (-0.23%)
     
  • NZD/EUR

    0.5553
    +0.0013 (+0.23%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    84.10
    +0.53 (+0.63%)
     
  • GOLD

    2,345.10
    +2.60 (+0.11%)
     
  • NASDAQ

    17,708.79
    +278.29 (+1.60%)
     
  • FTSE

    8,144.36
    +65.50 (+0.81%)
     
  • Dow Jones

    38,214.37
    +128.57 (+0.34%)
     
  • DAX

    18,162.56
    +245.28 (+1.37%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.4330
    +0.9370 (+1.01%)
     

Teva Pharmaceutical: Still Focused on New Product Launches

Teva Pharmaceutical: Still Focused on New Product Launches

Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.